The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
 
Vaia Florou
No Relationships to Disclose
 
Wungki Park
No Relationships to Disclose
 
Peter Joel Hosein
Consulting or Advisory Role - Angiodynamics; AngioDynamics; Autem Medical; Celgene; Ipsen; Medtronic
Research Funding - AstraZeneca (Inst); Boston Biomedical (Inst); Kite, a Gilead company (Inst)
 
Breelyn A. Wilky
Consulting or Advisory Role - Immune Design; Janssen Oncology; Lilly; Novartis
Research Funding - Agenus; ArQule; Daiichi Sankyo; Merck Sharp & Dohme; Novartis
Travel, Accommodations, Expenses - Advenchen Laboratories; Agenus; Lilly; Novartis
 
Jonathan C. Trent
Honoraria - GlaxoSmithKline
Consulting or Advisory Role - Janssen; Lilly; Novartis
 
Gilberto Lopes
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Tesaro (Inst)